AstraZeneca are taking a keen interest in cell therapy for cardiovascular disease. Here the Global Head of Research and Early Clinical Development at AstraZeneca is talking about MESO’s dream trial:
“There are also mesenchymal stem cells-based approaches in the clinic today and some rather large Phase 3 trials are being finalized this year. It will be interesting to see the outcome of these!”
Phase 3 DREAM HF-1 read-out, page-272
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.070(6.54%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 99.5¢ | $8.525M | 8.377M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 261779 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 68349 | 12 |
View Market Depth
| Last trade - 15.49pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |